

Diversity and origin of hepatitis C virus infection among unpaid blood donors in the Netherlands

Thijs J.W. van de Laar, Marco H.G.M. Koppelman, Akke K. van der Bij, Hans L. Zaaijer, H. Theo M. Cuijpers, Cees L. van der Poel, Roel A. Coutinho, and Sylvia M. Bruisten

BACKGROUND: To improve transfusion policy and to increase understanding of the spread of hepatitis C virus (HCV) in the general population, HCV infections among voluntary Dutch blood donors were examined with molecular epidemiologic techniques.

STUDY DESIGN AND METHODS: During 6 years, 1997 through 2002, confirmed anti-HCV-positive donors were interviewed on HCV-associated risk behavior with a standardized questionnaire. Additionally, HCV isolates were genotyped, partially sequenced, and compared to sequences obtained from Dutch injecting drug users (IDUs).

RESULTS: HCV prevalence and incidence rates among Dutch donors were extremely low; the residual risk of transmitting HCV was calculated to be 1 in 30 million donations. Former IDUs (21%), transfusion recipients (30%), and immigrants (>12%) were identified as major HCV risk groups. Cryptogenic transmission caused 18 percent of infections among new donors and all infections among repeat donors. Compared to IDUs, genotype distribution among donors was highly diverse; major subtypes were 3a (27%), 1a (24%), 1b (24%), 2a/b (10%), and 4 (9%). Half of the donors were infected with IDU-related subtypes 1a and 3a, whereas subtype 1b mainly spread via blood transfusion and various other nosocomial modes of transmission in the past. HCV infections acquired in endemic countries could be clearly identified based on genotype.

CONCLUSION: Different modes of transmission are linked to infections with certain HCV subtypes, suggesting separate HCV epidemics, but spillover between different risk groups underlines the value of molecular epidemiologic techniques to gain insight into the origin and dynamics of HCV infections on a population level.

Transfusion-transmissible pathogens such as the hepatitis C virus (HCV) remain of major concern for the safety of blood supplies. In industrialized countries, introduction of increasingly sensitive and new laboratory tests have greatly improved blood safety over the past decades, as have indirect strategies such as no payment, donor education, call-back procedures, and history-based donor selection.^{1,2} Currently, residual contamination risk for HCV in the United States is estimated to be 1 per 800,000 donations for new donors and 1 per 2,000,000 donations for repeat donors.³

HCV infection persists in 60 to 85 percent of persons infected and can, over decades, lead to serious liver-related illness and death.^{4,5} Sharing of injection equipment among injecting drug users (IDU) accounts for most HCV infections in industrialized countries.⁶ Until the introduction of diagnostic screening in 1991, HCV could also be transmitted through blood, blood products, hemodialysis, and organ transplantation.⁷ In developing countries, unsafe injection practices and nonsterile medical procedures may still account for significant HCV transmission and serve as a bridge to the general population;⁸

ABBREVIATIONS: IDU(s) = injecting drug user(s); IQR = interquartile range.

From the Department of Infectious Diseases, Health Service, Amsterdam; the Research and Diagnostics Services Division, Sanquin, Amsterdam; the Department of Human Retrovirology, Academic Medical Center/University of Amsterdam, Amsterdam; and the Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands. Financial support was provided by zon MW grant number 912-03-005.

Address reprint requests to: Thijs van de Laar, MSc, Health Service Amsterdam, Cluster Infectious Diseases, Nieuwe Achtergracht 100, 1018 WT Amsterdam, the Netherlands; e-mail: tvdlaar@ggd.amsterdam.nl.

Received for publication December 9, 2005; revision received March 1, 2006, and accepted March 1, 2006.

doi: 10.1111/j.1537-2995.2006.00961.x

TRANSFUSION 2006;46:1719-1728.

in developed countries, however, such nosocomial transmission is assumed to be restricted to incidental events.^{9,10} In the Netherlands, prevalence rates are known for high-risk groups like IDU (30%-90%),^{11,12} persons with hemophilia (44%),¹³ and dialysis patients (3.5%),¹⁴ but little is known about seroprevalence and mode of transmission in the general population. Recent estimations suggest that HCV is carried by 0.1 percent of the Dutch population, of whom the majority (50%-70%) do not know that they are infected.^{12,15} This lack of awareness clearly affects blood safety. Donor selection methods seem to be a cost-effective way to reduce the risk of transfusion-related HCV transmission, but they depend on donor awareness, recallability, and reliability of reporting past risk behavior.^{1,2}

The large genetic variability of the HCV genome has led to a proposed consensus of six genotypes and numerous closely related subtypes.¹⁶ Genotype distribution differs by geographic region and by year and mode of transmission.^{17,18} For HCV as well as other viruses, molecular epidemiology has proven a useful tool to identify risk groups and to distinguish different routes of transmission.¹⁹⁻²¹ In western Europe, HCV subtypes 1a and 3a predominate among IDUs,^{22,23} whereas subtypes 1b and genotype 2 are mainly associated with, especially in older patients, contaminated blood transfusions, and other types of nosocomial transmission.^{14,24-27}

To improve transfusion policy, it is essential to increase the understanding of HCV dispersal in the general population and to elucidate risk profiles of subjects still unaware of their positive HCV status. We therefore studied risk behavior of HCV-positive donors in the Netherlands from 1997 through 2002. To obtain more detailed information on the origin of HCV infection among Dutch donors and to investigate whether endemic HCV donor strains exist in the Netherlands, HCV donor isolates were genotyped, sequenced, and compared to HCV strains circulating among IDU.

MATERIALS AND METHODS

Study population

Participants (n = 99) included all new and repeat blood and plasma donors in the Netherlands who tested HCV-positive during the 6-year period 1997 through 2002. Repeat donors were defined as those already registered in the Dutch blood banks who had at least one HCV-negative donation after HCV diagnostic screening was introduced in 1991. New donors were those either who had never donated in the Netherlands (candidate donors) or whose last HCV-negative donation predated 1991 (irregular donors). For all participants, history-based donor selection had failed; none had been kept from donating based on a preceding questionnaire dealing with past risk behavior.

Routine HCV screening in the Netherlands

Donor plasma samples were tested with the screening and confirmation algorithm prescribed at the time of sampling by national guidelines concerning detection and notification of donors and recipients of HCV-infected blood. The college of blood transfusion of the Dutch Red Cross officially established these guidelines. During the period 1997 through 1999, routine HCV screening relied on the detection of HCV antibodies only (Abbott PRISM, Abbott Laboratories, Abbott Park, IL); HCV-seropositive samples were confirmed with Immunoblot assays and polymerase chain reaction (PCR). Since 1999, in addition to HCV serologic screening, nucleic acid testing (NAT) minipool screening has been performed on all samples.²⁸

HCV prevalence, incidence, and residual risk

HCV prevalence among donors was calculated by dividing the number of confirmed HCV-positive new donors by the total number of new donors in that period. HCV incidence rate is the number of repeat donors that seroconverted during the study period divided by the number of person-years, that is, the time between the first and last donation of each donor during the study period. The residual risk of transfusion-transmitted HCV infection was estimated according to the incidence-rate/window-period model as described by Schreiber and coworkers.⁷ Window periods used for HCV serologic screening (66 days) and HCV NAT screening (10 days) were those reported by Busch.²⁹

Epidemiologic data

All new and repeat donors who tested HCV-positive were invited to the blood bank for medical counseling and repeat testing to exclude any possible identification errors. During medical counseling, donors were asked to complete a survey to clarify the possible route of HCV transmission. A questionnaire concordant with that of Orton and colleagues³⁰ was used, elaborately dealing with known and potential risk factors for acute and/or lifetime HCV exposure.³¹ Supplementary to the guidelines for hepatitis surveillance and case management (CDC, January 2005), additional questions regarding the donor's demographic characteristics, health, sexual habits, travel behavior, and history of other infectious diseases were included. No information on dental work and/or oral surgery and incarceration was obtained. Questionnaires were administered in a face-to-face interview, conducted by a transfusion physician. Based on the questionnaire, the most plausible route of transmission was determined for each donor. Transmission routes were classified into five hierarchical categories: 1) injection drug use; 2) blood transfusion received before 1991; 3) endemic exposure (i.e., individuals born in countries with a HCV seroprevalence exceeding 2.0%);¹⁵ 4) parenteral and/or invasive

exposure other than drug use or transfusion (needle-stick injuries, unhygienic injections, tattoos, piercing, acupuncture, surgery, endoscopy); and 5) cryptogenic exposure (e.g., nosocomial, occupational, sexual, intrafamilial). Donors reporting more than one possible mode of transmission were classified into the risk category of the highest hierarchical order. For donors who reported no risks ($n = 6$) cryptogenic exposure was assumed.

HCV RNA isolation and amplification

Index samples from HCV RNA-positive new donors and the seroconversion samples of repeat donors were collected retrospectively. RNA isolation was performed on 100 μ L of plasma with the TriPure method (Roche Diagnostics, Almere, the Netherlands) based on extraction once with a phenol and guanidium thiocyanate solution, followed by a chlorophorm extraction and an ethanol precipitation of the water phase. The pellet was washed and dissolved in 50 μ L Tris-HCL buffer, pH 8.0. Samples had been stored at -80°C . Part of the HCV NS5B region was amplified with a nested multiplex reverse transcription (RT)-PCR method devised to amplify HCV RNA of genotypes 1-4.²² Primers were those described by Van de Laar and associates.¹¹ To extend the specificity of the NS5B PCR to a greater variety of strains, additional primer sets for genotype 5 and subtype 3k were designed (see Table 1). Strains of genotype 6 were detected with a nested multiplex RT-PCR based on the HCV core region.¹¹

Genotyping and phylogenetic analysis

NS5B PCR products were ethanol precipitated. Sense and antisense strands were separately cycle-sequenced with a cycle sequencing system (BigDye Terminator system, version 1.1, Perkin Elmer, Monza, Italy). Sequence products were purified with spin kits (DyeEx, Qiagen, Venlo, the Netherlands) and analyzed on an automated sequencer (ABI-310, Applied Biosystems, Nieuwerkerk a/d IJssel, the

Netherlands). Sequence alignment of the 420-bp NS5B fragment and translation into its 140 amino acids was performed with computer software packages (BioEdit³² and GeneDoc [available from <http://www.psc.edu>]). Another computer program (Mega version 3.1; available from <http://www.megasoftware.net>) was used to construct a phylogenetic tree through its amino acid model, with Poisson correction. Bootstrap values ($n = 1000$) were calculated to analyze the stability of tree topology.

Viral genotype was identified after phylogenetic analysis of the NS5B sequences obtained (GenBank Accession Numbers DQ238625 to DQ238706) along with reference sequences of 18 confirmed HCV subtypes.¹⁶ If subtyping failed due to the absence of a confirmed reference sequence, the preceding 237 bp of the amplified NS5B fragment were determined with a nested RT-PCR, as described by Cochrane and coworkers.²³ Subsequent subtyping was done with the NS5B reference sequences of 58 provisionally assigned HCV subtypes described by Simmonds and colleagues.¹⁶

IDU database

Individuals who pass history-based donor selection were assumed to represent a very low to no-risk group. Their HCV sequences were compared to sequences in our IDU database. IDU were participants of the Amsterdam Cohorts Studies among drug users or visitors of the various drug health care institutions in Amsterdam.¹¹ HCV RNA-positive blood donors were matched to HCV RNA-positive IDUs, such that the distribution of birth year and sex were similar for both groups. IDUs were sampled between 1985 and 2004.

Statistical analysis

Differences in age and sex between individuals who were interviewed and those not interviewed, as well as differences in HCV prevalence among new donors over time,

TABLE 1. Primer sets targeting the NS5B region of HCV genotypes 5 and 3k*

Primer	Sequence (5'→3')	Nucleotide position†	Specific for genotype
5-OS	TTCACCACTAGTATGGGCAA	8113-8132	5
5-OA1	CAAGCTTCCTGAGGCAACTA	8718-8737	5
5-OA2	CTCGGAGAGTATGAATGGA	8681-8699	5
5-IS	CCATGACGTGCTACATTAAGG	8135-8175	5
5-IA	TGAAAACGCGCTAAGTCCAT	8660-8679	5
3k-OS	AAAGCAAAGGCAGCCACCAA	8152-8172	3k
F3a‡ (OA)	TCTACTGGAGAGTAACTGTGGA	8681-8703	3k
3k-IS	TGTCTGCGGAGACGACTTGGT	8201-8222	3k
3k-IA	CCATGGAGTCGTTCAATGATGG	8642-8663	3k

* All primers are expected to show some degree of cross-hybridization to targets of other genotypes. A = antisense; I = inner PCR; O = outer PCR; S = sense.

† Numbered as in Choo et al.⁴⁷

‡ Primer described by van Asten et al.²² specific for genotype 3a.

TABLE 2. HCV prevalence, incidence rate, and residual risk among Dutch donors

Period	New donors				Repeat donors			
	Number of HCV-positive donors		Total number of new donors	Prevalence per 100,000 new donations (95% CI)	Number of HCV seroconversions*/total number of person-years	Incidence per 100,000 repeat donor person-years (95% CI)	Window period in days	Residual risk per 1,000,000 repeat donor person-years (1:repeat donations)
	Candidate donors	Irregular donors*						
1997-1999	56	3	179,817	32.8 (24.4-41.2)	3/1,919,000	0.16 (0.12-0.21)	66	0.28 (1:3,500,000)
2000-2002	33	2	190,700	18.4 (12.3-24.4)	2/1,729,000	0.12 (0.09-0.17)	10	0.03 (1:31,500,000)
1997-2002	89	5	371,517	25.3 (20.2-30.5)	5/3,648,000	0.14 (0.11-0.18)		

* Due to a stricter definition, the number of HCV-positive repeat donors in this study ($n = 5$) differs from the number noted in the annual reports of the blood bank ($n = 10$). We categorized irregular whose last donation was from before the introduction of diagnostic screening in 1991 as new donors (prevalent cases), whereas they were classified as repeat donors (incident cases) in the annual reports. Classification of irregular donors as incident cases would have resulted in an HCV incidence rate of 0.27 (95% CI, 0.23-0.32) per 100,000 repeat person-years.⁴⁶

were tested by the chi-square test. Differences in genotype distribution between donors and IDU were tested by the Fisher exact test; genotypes were categorized into 6 subtypes: 1a, 1b, 2a/b, 3a, and 4d and other genotypes. Two software packages (SPSS, SPSS Inc., Chicago, IL; and S-PLUS, Insightful Corp., Seattle, WA) were used.

RESULTS

HCV prevalence, incidence, and residual risk

From 1997 through 2002, 370,517 new donors registered at the Dutch blood banks, whereas repeat donors accounted for a total follow-up time of approximately 3,648,000 person-years (Sanquin, annual reports 1997-2002). In total, 99 donors were confirmed HCV-positive in routine diagnostic screening: 94 new donors and 5 repeat donors. HCV prevalence significantly declined over time from 32.8 (1997-1999) to 18.4 (2000-2002) per 100,000 new donors (Table 2). HCV incidence rates did not change and remained low, approximately 0.14 per 100,000 repeat donor person-years. Owing to the introduction of HCV NAT screening in 1999, however, residual risk decreased almost 10-fold from 1:3,500,000 donations in 1997 through 1999 to 1:31,500,000 donations in 2000 through 2002 (Table 2).

Epidemiologic data

New donors. Of 94 HCV-seropositive new donors, 73 (78%) returned to the blood bank for medical counseling and interviews regarding risk behavior. This high participation rate^{25,30} and the fact that respondents were similar to nonrespondents in median age and sex (Table 3) suggests that epidemiologic data truly reflect the HCV-positive Dutch donor population. As to reported risk behavior, more than 50 percent of respondents had either injected drugs or had received blood products before 1991 (Table 3). Remarkably, 48 of 73 (66%) respondents had lived outside the Netherlands for a period longer than 1 year; 41 of 73 (56%) lived abroad for more than 5 years

TABLE 3. General characteristics and risk behavior of HCV-positive new donors

HCV-seropositive new donors	Total (%)
Nonrespondents ($n = 21$)	
Median age (years)	46 (IQR 38-50)
Percent male	59
Respondents ($n = 73$)	
Median age (years)	41 (IQR 34-48)
Percent male	58
Risk according to risk category*	
1. Injecting drug use	15 (21)
2. Blood transfusion before 1991	22 (30)
3. Born in endemic countries	9 (12)
4. Other parenteral transmission	14 (19)
5. Cryptogenic transmission	13 (18)

* Risk categories are specified in the text (see Materials and Methods).

(data not shown). Moreover, 18 new donors had donated blood before: 13 in foreign countries and 5 in the Netherlands (irregular donors). Risk behavior varied from injecting drug use (4×), blood transfusion before 1991 (6×), endemic exposure (1×), parenteral and/or invasive exposure excluding drug use and transfusion (4×), and cryptogenic exposure (3×). Most likely, at least 13 of these 18 subjects donated HCV-contaminated blood at least once. All last donations predated 1991 (data not shown).

Repeat donors. Only five repeat donors seroconverted for HCV during the study period; they all returned to the blood bank for medical consultation and interviews regarding past risk behavior. All five were born in the Netherlands, four of five were female, and the median interdonation interval, the time between last HCV-negative and first HCV-positive donation, was 0.80 year (interquartile range [IQR], 0.40-2.0) (Table 4). One repeat donor (Donor 2), a psychiatric nurse, had a relatively large interdonation interval of 3 years. She reported no needle-stick injuries but did report accidents involving biting and the spraying of blood. Donor 53, a 55-year-old man, reported no risk behavior except for hospitalization in Belgium after a car crash. He received no blood products but, with

TABLE 4. General characteristics and risk behavior of repeat donors seroconverting for HCV

Repeat donor	Donor					Seroconversion		RNA		Risk behavior	
	Donor number	Sex	Age (years)	Country of birth	Number of donations*	Year	IDI (year)	RNA	Genotype	Category	Risk factor
1	2	Female	35	NL	>2†	1997	3	Yes	1b	5	Occupational: mental health care
2	53	Male	55	NL	77	1997	0.3	Yes	NT	5	Nosocomial: hospitalization
3	56	Female	42	NL	5	1997	0.9	Yes	3a	5	Sexual/household partner HCV-pos
4	72	Female	56	NL	28	2002	0.5	Yes	3a	5	Sexual/household partner HCV-pos
5	93	Female	40	NL	28	2002	0.8	No	RNA-neg.	5	Sexual/household partner HCV-unk

* Number of donations prior to HCV seroconversion.

† The exact number of donations before the last HCV-seronegative donation in 1994 could not be determined.

IDI = interdonation interval; NL = the Netherlands; unk. = unknown; NT = not typable.

TABLE 5. HCV genotype distribution among Dutch blood and plasma donors according to mode of transmission

Mode of transmission	Transmission category							RNA-negative donors	Total number of samples
	1a	1b	2a/b	3a	4a	4d	Other*		
IDU-related†	5‡	2	0	8‡	0	1	0	4	20
Transfusion	5‡	8‡	1	4	0	0	0	4	22
Endemic	1	1	0	0	3‡	0	4‡	0	9
Other parenteral	3	3	1	3	0	0	1	2	13
Nonparenteral	1	4	1	3	0	1	0	1	11
No data	5‡	2	5‡	4	0	1	0	2	19
Total	20	20	8	22	4	3	4	13	94§
Genotype distribution (%)	24	24	10	27	5	4	5		

* Other subtypes comprises HCV subtypes 1g, 2c, 2e, 3k, and 4k.

† IDU-related refers to donors that injected drugs in the past (n = 15) as well as donors that contracted HCV from an IDU by sexual or occupational contact (n = 6).

‡ For each genotype, the transmission category with the highest number of isolates.

§ Actually, 99 donors were HCV-positive but four samples were not available for genotyping, and one sample could not be genotyped.

severe cuts and bruising, he had stitches and was put on an intravenous drip. The remaining three women (Donors 56, 72, and 93) initially appeared to lack any form of risk behavior. All three, however, reported a new heterosexual partner. On questioning, two of these partners (Partners 56 and 72) admitted to a history of injecting drug use. Both their corresponding donors (Donors 56 and 72) were infected with IDU-related genotype 3a. Blood of Partner 72 was investigated revealing that he and Donor 72 had 100 percent identical HCV nucleotide sequences. A history of shared injecting drug use seemed unlikely. Both Partner 56 and Partner 72 quit injecting (long) before they met Donors 56 and 72, respectively, and both donors genuinely denied being aware of the fact that their new partners were ex-IDUs. Sexual and/or household exposure, therefore, remained as the most plausible routes of HCV transmission.

Sequencing, genotyping, and phylogenetic analysis

The samples of 86 of 99 HCV-positive donors were positive for the presence of HCV RNA. Of these, 4 were unavailable

for study and in 1 sample, genotyping and sequencing failed for unknown reasons. Thus, 81 NS5B HCV sequences were obtained.

Figure 1 represents a phylogenetic tree of 14 reference sequences and all 81 donor sequences. Donor sequences are shown with their assumed mode of transmission and allocated risk category. All donor strains belong to HCV genotypes 1 through 4; no strains of genotype 5 or 6 were observed. HCV isolates of Donor 80 and Donor 91 could only be subtyped by amplification and sequencing of a different part of the NS5B gene for which a complementary reference sequence was available; they were eventually subtyped 1g and 4k, respectively. HCV subtypes 3a (27%), 1a (24%), 1b (24%), 2a/b (10%), 4a (4%), and 4d (4%) were the most prevalent; the remaining 6 percent belonged to various other subtypes. Different modes of transmission were not randomly distributed among HCV subtypes. HCV subtypes 3a (50%) and 1a (31%) predominate among donors who reported injecting drug use or close contact with IDU (Table 5). Donors infected with subtype 1b mainly reported a history of blood transfusion (44%) or other nosocomial modes of transmission (Fig. 1).




Fig. 1. HCV phylogenetic tree (NS5B) of Dutch blood and plasma donors (1997-2002). Neighbor-joining tree based on amino acid model with Poisson correction (amino-acid 2736-2875). Risk category and risk behavior are listed opposite each sequence. Strains from donors lacking epidemiologic data were labeled "no data."

The appearance of foreign subtypes is associated with endemic exposure: subtype 1g from Sudan, subtype 4a from Egypt, subtype 4k from Rwanda, and subtypes 2e and 3k from Indonesia. The only foreign strain not related to endemic transmission (subtype 2c) was isolated from

an Italian woman who had acquired a tattoo under unhygienic conditions in Switzerland. Indeed, subtype 2c is highly prevalent in the Mediterranean area, especially in Italy. Remarkably, five of the eight subjects infected with genotypes 2a or 2b did not return to the blood bank and hence were not interviewed. The others reported transmission through tattooing in the United Kingdom (2b), hospitalization in Germany (2b), and a blood transfusion in the United Arab Emirates (2a).

The genotype distribution among blood donors is significantly different ($p < 0.001$) from that of a matched population of IDUs (Fig. 2A). Among donors, genotype distribution is more diverse; 12 percent of strains belong to subtypes absent among IDUs. Among donors subtypes 1a (25% vs. 51%) and 3a (28% vs. 38%) are less abundant than among IDUs, and subtype 1b (25% vs. 5%) is more abundant. Separate phylogenetic trees were made of IDU-related HCV subtypes 1a and 3a to investigate whether separate clustering would distinguish HCV strains from IDUs, donors who reported injecting drug use or close contact with IDUs (IDU-related risks), and donors who denied IDU-related risks (Fig. 2B). Sequences of donors that denied IDU-related risks were phylogenetically interspersed with IDU sequences suggesting mixing of the virus between the different risk groups. For different routes of transmission, however, an intermediate level of clustering was observed within these subtrees. For subtype 3a, the upper part of the tree (Cluster I) is dominated by IDUs, including 6 of 8 donors who reported IDU-related risks. In fact, Cluster I comprises only 2 donors who denied IDU-related risks. One of them reported no risk at all (Donor 30), but was infected with a strain identical to that of 2 IDUs (IDUs 21 and 95). In contrast, the lower part of the tree (Cluster II) is dominated by donors who denied IDU-related risks. For subtype 1a, the distinction between IDU and donors that denied IDU-related risks is less pronounced. Nonetheless, 8 of 20 donor isolates were identical (Cluster III); Cluster III, however, comprises both donors that reported injecting drug use and donors that denied IDU-related risks. Cluster IV comprises 8 identical isolates from IDUs. Strikingly, one isolate (Donor 86) of a donor that denied injecting drug use but did report a blood transfusion was also identical.

DISCUSSION

HCV prevalence rates among blood and plasma donors in the Netherlands are among the lowest ever reported in the world and still declining. HCV incidence rates have stabilized over time, 0.14 per 100,000 donor years in the period 1997 through 2002, but were lower than, for example, in Spain (3.70),³³ the United States (1.89),³ Germany (1.50),³⁴ Canada (1.35),³⁵ France (0.34),^{36,37} and the United Kingdom (0.23).³⁸ Despite unchanged incidence rates, the introduction of NAT screening in 1999 has drastically




Fig. 2. Comparing HCV strains from Dutch donors with HCV strains from a matched population of IDU in the Netherlands. (A) HCV genotype distribution among Dutch IDU and Dutch blood and plasma donors. (B) Neighbor-joining phylogenetic trees of donors and IDU of HCV subtypes 1a and 3a (NS5B region, amino acid 2736-2875, amino acid model with Poisson correction).

decreased the residual risk of transmitting HCV through contaminated blood products. Based on data from the entire Dutch donor population, this risk is now 1 in approximately 31,500,000 repeat donations. Underestimation due to laboratory error, new or rare viral variants not being recognized by the assay, and the fact that estimated residual risk of new donors exceeds that of repeat donors cannot be entirely excluded.^{37,38} In contrast, the incidence-rate/window-period model used to calculate the residual risk assumes infectivity of the virus throughout the window period, an assumption that, if invalid could result in overestimation.⁷

Donor-selection methods were invented to minimize the risk of viral transmission, especially during the window period of infection. Unfortunately, not all risky donors are filtered out.^{1,2} Three major risk profiles were identified: contaminated blood transfusions received in the past, a history of injecting drug use, and immigration and/or traveling. As in France,²⁵ injecting drug use and contaminated blood transfusions accounted for more than 50 percent of HCV infections among new donors. To prevent possible contamination with prions causing variant Creutzfeldt-Jacob disease, recipients of blood after 1980 have been excluded from donation only since April 2005. A further decrease of the number of HCV-positive new donors passing donor selection will be an indirect result of this measure. Current or former IDU, however, has always been a donor exclusion criterion, yet 21 percent of HCV-positive new donors were former IDUs. Except for one donor who had injected drugs until 1 year before HCV screening, median time since last injection was 20 years (IQR, 13-26 years). Given this length of time and the alteration of lifestyle, lack of identification with the "drug addict" stereotype, and the absence of health complaints, former IDUs might be incapable of self-reference with regard to the risks they took.^{30,39} Deliberately concealed HCV risk behavior, however, should not be ruled out. General education programs on HCV have increased the awareness of risks associated with former drug use, perhaps causing ex-IDUs to register as donors primarily to obtain free and anonymous HCV testing.⁴⁰

The third risk profile was immigration and long-time residence abroad. Among HCV-positive new donors, 56 percent had lived in foreign countries for more than 5 years. Of these, 40 percent had lived in HCV-endemic countries and 30 percent in countries with HCV prevalences exceeding 1 percent. Import of HCV from countries with intermediate to high HCV prevalences should not be underestimated, especially because migration to European countries continues to increase. Recent estimates suggest that first-generation immigrants are responsible for 56 percent of HCV infections in the Netherlands.¹² HCV prevalences in former Dutch colonies like Surinam (5.5%) and Indonesia (2.1%), as well as countries like Morocco (1.3%) and Turkey (1.5%) where large groups of immigrants

originate, exceed those of the Netherlands by a factor of 10 to 55.¹⁵ But also within the European Union, in countries like Italy and Greece, HCV high-endemic areas exist.^{26,41}

Although participants were stimulated to reflect upon past risk behavior by confronting them with a confirmed positive HCV test result, recall bias might have influenced the results. Indeed, 40 percent of HCV infections among new donors could not be explained by the three risk profiles identified and were eventually classified as "other parenteral" or "cryptogenic." For these donors, identification of the exact source of HCV infection was hampered by long acquisition times and the lack of HCV-negative donor controls.³⁰

Acquisition time was limited for HCV-positive repeat donors. Recent acquisition and hence the possibility of donation within the window-period of infection poses a serious threat to the blood supply. In the United States, 35 to 40 percent of HCV-positive repeat donors admitted to recent injection drug use or recent incarceration (a potential marker for injecting drug use).³⁰ None of the five HCV-seroconverting Dutch donors, however, admitted to the use of any drugs at all. HCV seroconverting Dutch as well as Italian donors⁴² only reported cryptogenic exposure, risk behavior for which they cannot be excluded from donation. Heterosexual and/or household exposure was plausible for three of five Dutch HCV-positive repeat donors. Although heterosexual HCV transmission is rare, in some countries sexual partners of HCV-positive subjects are excluded from blood donation. None of the three repeat donors who possibly contracted HCV through sex, however, was aware of former risk behavior or the HCV status of their new sexual partner.

The HCV genotypic pattern among Dutch donors resembles the pattern of other western European countries in that HCV subtypes 1a, 1b, and 3a account for 80 to 90 percent of total infections, whereas genotypes 2 and 4 each contribute 5 to 10 percent.^{6,25,26,43} Donor populations in the United States (and Italy), however, typically show higher rates of HCV genotype 2 (up to 25%), and in the United States genotype 4 seems absent.^{24,30} The genotypic pattern mainly depends on geographic origin, route of transmission, and year of infection.¹⁸ The latter is clearly reflected within the three risk profiles identified. In line with the recent introduction of genotype 4 into Europe by immigrants from Africa and the Middle East,^{22,44} the presence of rare HCV subtypes among Dutch donors was directly associated with immigration and traveling. With respect to the more prevalent genotypes, the majority of infections with subtypes 1a and 3a were traced back to former injecting drug use, whereas subtype 1b was mainly contracted through blood transfusions and medical interventions.^{25,26,43} The worldwide distribution of genotype 2, its wide genetic diversity within the Dutch population, as well as the risk behavior reported suggest long-standing nosocomial transmission.^{14,26,41,45,46}

Although acquisition time might have skewed the observed genotype distribution, and natural virus evolution might have obscured the phylogenetic identification of transmission networks, the observed differences in epidemiology between the spread of subtypes 1a and 3a on the one hand and the spread of subtypes 1b and 2 on the other suggest two independently developing epidemics, one IDU-related and the other donor-related. The introduction of donor screening in the early 1990s halted the expansion of transfusion-related strains (1b and 2).^{6,27,43} Indeed, history-based modeling shows that in many countries, transfusion-related strains initially had exponential growth followed by hampered growth, gradual decline, and finally replacement by strains linked to injecting drug use (1a and 3a).²⁰ Our data, however, provide strong evidence that IDU-related subtypes 1a and 3a have spread beyond the boundaries of the IDU scene via high-risk sexual behavior, occupational contact, and blood donations of former IDU.⁴⁶ Incidental spillover from IDUs to the general population is confirmed by the observed levels of phylogenetic mixing between IDU- and donor-related HCV sequences within subtypes 1a and 3a (Fig. 2).⁴⁶ In contrast, introduction of new genotypes from low- to high-risk populations as a result of migration can explode rapidly into new epidemics.^{11,17,22}

In conclusion, current donor-selection methods in the Netherlands appear highly effective for HCV. HCV prevalence, incidence, and residual risk among Dutch donors are extremely low. Among new donors, donor selection incidentally misses HCV-positive recipients of blood and blood products before 1991, former IDUs, and first-generation immigrants. HCV-positive repeat donors, however, reported only low-risk cryptogenic modes of transmission that are impossible to detect by preliminary screening of risk behavior. Although in the Netherlands different HCV subtypes have spread via different transmission networks, phylogenetic analysis proves that incidental spillover from high-risk groups to the general population does occur, mainly through cryptogenic modes of transmission.

REFERENCES

- Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. *Retrovirus Epidemiology Donor Study*. *JAMA* 1997;277:967-72.
- van den Burg PJ, Vrieling H, Reesink HW. Donor selection: the exclusion of high risk donors? *Vox Sang* 1998;74(Suppl 2):499-502.
- Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion* 2002;42:975-9.
- Jauncey M, Micallef JM, Gilmour S, et al. Clearance of hepatitis C virus after newly acquired infection in injection drug users. *J Infect Dis* 2004;190:1270-4.
- Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med* 2001;345:41-52.
- Trepo C, Pradat P. Hepatitis C virus infection in Western Europe. *J Hepatol* 1999;31(Suppl 1):80-3.
- Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. *N Engl J Med* 1996;334:1685-90.
- Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. *Lancet Infect Dis* 2002;2:293-302.
- Forns X, Martinez-Bauer E, Feliu A, et al. Nosocomial transmission of HCV in the liver unit of a tertiary care center. *Hepatology* 2005;41:115-22.
- Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. *Ann Intern Med* 2005;142:898-902.
- van de Laar TJ, Langendam MW, Bruisten SM, et al. Changes in risk behavior and dynamics of hepatitis C virus infections among young drug users in Amsterdam, the Netherlands. *J Med Virol* 2005;77:509-18.
- Kretzschmar M. De prevalentie van hepatitis C in Nederland [in Dutch]. Bilthoven RIVM internal report project V/210041. 2004. p. 1-13. <http://www.RIVM.nl>.
- Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. *Blood* 2004;104:3494-500.
- Schneeberger PM, Keur I, van Loon AM, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. *J Infect Dis* 2000;182:1291-9.
- World Health Organisation. Hepatitis C—global prevalence (update). *Wkly Epidemiol Rec* 1999;74:425-7.
- Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* 2005;42:962-73.
- Schroter M, Zollner B, Laufs R, et al. Changes in the prevalence of hepatitis C virus genotype among injection drug users: a highly dynamic process. *J Infect Dis* 2004;190:1199-200.
- Zein NN. Clinical significance of hepatitis C virus genotypes. *Clin Microbiol Rev* 2000;13:223-35.
- van Steenberghe JE, Tjon G, van den Hoek A, et al. Two years' prospective collection of molecular and epidemiological data shows limited spread of hepatitis A virus outside risk groups in Amsterdam, 2000-2002. *J Infect Dis* 2004;189:471-82.
- Nakano T, Lu L, Liu P, et al. Viral gene sequences reveal the variable history of hepatitis C virus infection among countries. *J Infect Dis* 2004;190:1098-108.
- Koppelman MH, Zaaijer HL. Diversity and origin of hepatitis B virus in Dutch blood donors. *J Med Virol* 2004;73:29-32.

22. van Asten L, Verhaest I, Lamzira S, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. *J Infect Dis* 2004;189:292-302.
23. Cochrane A, Searle B, Hardie A, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. *J Infect Dis* 2002;186:1212-21.
24. Dal Molin G, Ansaldi F, Biagi C, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. *J Med Virol* 2002;68:352-6.
25. Elghouzzi MH, Bouchardeau F, Pillonel J, et al. Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. *Vox Sang* 2000;79:138-44.
26. Gerard C, Delwaide J, Vaira D, et al. Evolution over a 10 year period of the epidemiological profile of 1,726 newly diagnosed HCV patients in Belgium. *J Med Virol* 2005;76:503-10.
27. Payan C, Roudot-Thoraval F, Marcellin P, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. *J Viral Hepat* 2005;12:405-13.
28. Jongerius JM, Sjerps M, Cuijpers HT, et al. Validation of the NucliSens Extractor combined with the AmpliScreen HIV version 1.5 and HCV version 2.0 test for application in NAT minipool screening. *Transfusion* 2002;42:792-7.
29. Busch MP. Closing the window on viral transmission in blood transfusion. In: Stramer SL, editor. *Blood safety in the new millennium*. Bethesda: American Association of Blood Banks; 2001. pp. 33-54.
30. Orton SL, Stramer SL, Dodd RY, et al. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. *Transfusion* 2004;44:275-81.
31. Alter MJ. Prevention of spread of hepatitis C. *Hepatology* 2002;36:S93-S98.
32. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic Acids Symp Ser* 1999;41:95-8.
33. Alvarez M, Oyonarte S, Rodriguez PM, et al. Estimated risk of transfusion-transmitted viral infections in Spain. *Transfusion* 2002;42:994-8.
34. Offergeld R, Faensen D, Ritter S, et al. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-02: risk of virus transmission and the impact of nucleic acid amplification testing. *Euro Surveill* 2005;10:8-11.
35. Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. *CMAJ* 2003;169:767-73.
36. Pillonel J, Laperche S, Saura C, et al. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. *Transfusion* 2002;42:980-8.
37. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). *Euro Surveill* 2005;10:5-8.
38. Soldan K, Barbara JA, Ramsay ME, et al. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. *Vox Sang* 2003;84:274-86.
39. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med* 1996;334:1691-6.
40. Sharma UK, Schreiber GB, Glynn SA, et al. Knowledge of HIV/AIDS transmission and screening in United States blood donors. *Transfusion* 2001;41:1341-50.
41. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. *J Med Virol* 2005;76:327-32.
42. Prati D, Capelli C, Silvani C, et al. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors. *Hepatology* 1997;25:702-4.
43. Ross RS, Viazov S, Renzing-Kohler K, et al. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. *J Med Virol* 2000;60:122-5.
44. Schroter M, Zollner B, Schafer P, et al. Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. *J Clin Microbiol* 2002;40:1866-8.
45. Smith DB, Pathirana S, Davidson F, et al. The origin of hepatitis C virus genotypes. *J Gen Virol* 1997;78:321-8.
46. Pybus OG, Cochrane A, Holmes EC, et al. The hepatitis C virus epidemic among injecting drug users. *Infect Genet Evol* 2005;5:131-9.
47. Choo QL, Richman KH, Han H, et al. Genetic organization and diversity of the hepatitis C virus. *Proc Natl Acad Sci U S A* 1991;88:2451-5. 